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Abstract
Implementation of an Amiodarone Infusion Nurse Practice Guideline to Reduce the Incidence of
Phlebitis: A Quality Improvement Project
Kristen N. Cottrill
Background: Patients have an increased risk of developing phlebitis when amiodarone is
delivered through a peripheral intravenous catheter. In a 32-bed cardiac surgery step-down unit,
patients experienced phlebitis at a rate of 28.57% despite following manufacturer
recommendations. Individual interventions targeted at amiodarone-related phlebitis have
presented mixed results, however, when an amiodarone infusion practice guideline was
established, the rate and severity of phlebitis consistently decreased across studies. Purpose:
This project aimed to implement an evidence-based amiodarone infusion guideline to reduce
phlebitis development or severity in cardiac-surgery step-down patients without a central venous
catheter who received a peripheral intravenous infusion of amiodarone. Interventions: An
evidence-based amiodarone infusion nurse practice guideline was implemented after determining
the rate of phlebitis occurrence in the target population. A post-project staff survey was
conducted to determine satisfaction with using the guideline and perceived effectiveness at
reducing phlebitis. Methods: The amiodarone infusion nurse practice guideline was based on
similar guidelines identified during a comprehensive literature review. The post-project survey
was developed using feedback from project site leadership. Pre- and post-intervention data on
rates of phlebitis were each collected over a five-month period and the staff survey was
conducted after data collection was completed. Statistical analyses were performed to compare
pre- and post-intervention data. Results: The project included a total of 104 patients. The preintervention population consisted of 70 patients, of whom 16 people had developed a total of 20
incidences of phlebitis. The post-intervention population consisted of 34 patients, of whom 4
people had each experienced one incidence of phlebitis. Though not statistically significant,
phlebitis rates between pre-intervention and post-intervention data decreased 16.1%. Survey
results were inconclusive due to limited responses. Conclusion: Though not statistically
significant, implementation of this nurse practice guideline to reduce the incidence of phlebitis
made a clinically significant impact by reducing the incidence of phlebitis in patients receiving
peripheral intravenous infusions of amiodarone.
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Implementation of an Amiodarone Infusion Nurse Practice Guideline to Reduce the
Incidence of Phlebitis: A Quality Improvement Project
Phlebitis is a complication associated with intravenous medication administration. The
risk for phlebitis is reduced when caustic drugs are infused through a central venous catheter
(CVC). However, insertion or use of a CVC is not always feasible. In cardiac surgery patients,
amiodarone is a drug of choice for treating cardiac arrhythmias, but its use further increases the
risk for phlebitis when infused through a peripheral vein. The focus of the Doctor of Nursing
Practice project was to implement an evidence-based amiodarone infusion nurse practice
guideline (APG) to reduce the incidence of phlebitis in cardiac surgery step-down (CSD)
patients.
Problem Description
Spiering (2014) and Norton et. al., (2013) found a 25% to 85% incidence rate of phlebitis
in patients who received amiodarone infusions through a peripheral intravenous catheter (PIV).
In a large academic hospital on the east coast, it was estimated that step-down patients in a 32bed cardiac surgery step-down unit and 28-bed cardiovascular intensive care unit (CVICU)
developed phlebitis at an incidence rate of 20% following a peripheral infusion of amiodarone
(A. Litwinovich, personal communication, October 7, 2020). However, it was communicated
that phlebitis incidences were not always reported, and the 20% incidence rate was likely an
underestimation (A. Litwinovich, personal communication, October 7, 2020). An APG did not
exist within the project site’s healthcare system, but infusion practices reflected manufacturer
recommendations: use of an in-line filter, a PIV dedicated only to amiodarone, and infusion
through a CVC when possible.

2
Phlebitis is defined as inflammation of the vein wall. Signs and symptoms include pain,
tenderness, burning, redness, swelling, warmth, induration, and purulence at the PIV site (may
include a palpable cord) (Spiering, November/December 2014; Infusion Nurse Society,
January/February 2016; Oragano et al., February 2019). Phlebitis is graded based on severity:
grade 0 (absence of symptoms), grade 1 (redness with or without pain at the PIV catheter site),
grade 2 (pain with redness and/or swelling at the PIV catheter site), grade 3 (pain and redness at
the PIV catheter site, streak formation, and a palpable venous cord), and grade 4 (pain with
redness at the PIV catheter site, streak formation, palpable venous cord greater than 1 inch in
length, and purulent drainage) (Infusion Nurse Society, January/February 2016). Phlebitis is
further categorized into three types: chemical, physical, and infective (Oragano et al., February
2019). Chemical and physical phlebitis -caused by medication properties and poor catheter
insertion or maintenance, respectively- are associated with PIV amiodarone infusions and can
occur up to 96 hours after catheter removal (Oragano et al., February 2019; Murphy et al., 2020).
Phlebitis-related complications may include discomfort, fever, sepsis, increased length of
hospital stay and healthcare costs, and sometimes plastic surgery to repair the damaged tissue
(Mowry & Hartman, 2011; Mindo, August 2018).
Amiodarone is a class III antiarrhythmic medication commonly used off-label to treat
atrial fibrillation (AFib) and life-threatening ventricular tachyarrhythmias, but due to its physical
and chemical properties, it increases the likelihood of phlebitis when administered intravenously.
(Florek & Girzadas, August 2020). Amiodarone has a solution osmolality between 255 to 345
mOsm/L and a pH between 3.46 to 4.35, which increases the risk of damaging vein intima and
may result in chemical phlebitis (Gazitua et al., August 1979). Intravenous amiodarone infusions
may also lead to the formation of needle-shaped crystals that can damage local tissues (Ward &
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Yalkowsky, July/August 1993). Despite the increased risk for phlebitis, amiodarone remains the
gold standard for treating patients with tachyarrhythmias and its use has been recommended by
the American College of Cardiology, the American Heart Association, and the European Society
of Cardiology (Norton et. al., November 2013; Spiering, November/December 2014).
Hospitalizations due to AFib continue to rise in the United States, so concomitant rises in
phlebitis will likely occur in patients treated with intravenous amiodarone if evidence-based
practice (EBP) interventions are not implemented. Each year more than 454,000 people are
hospitalized for AFib in the United States, and an estimated 12.1 million people will have a
diagnosis of AFib by 2030 (CDC, September 2020). Between 2015 to 2017, cardiac arrhythmiarelated hospitalizations were highest in Central and Eastern United States (8.4 to 20.2 per 1,000
people) (CDC, September 2020). As hospitalizations for cardiac dysrhythmias increase -and
given the recommendation by the American College of Cardiology, American Heart Association,
and European Society of Cardiology to use amiodarone infusions- the incidence of phlebitis and
associated complications may continue to rise if EBP interventions are not implemented.
A direct cost associated with phlebitis-related complications has not been identified.
However, in 2017 hospital expenses for one day averaged between $3,949 and $15,734 for
hospital length of stay, and Healthcare.gov (n.d.) reported a 3-day hospital stay costs an
estimated $30,000 (Debt.org, n.d.). A lengthier hospital stay and increased use of medical
resources to treat phlebitis-related complications may substantially increase healthcare expenses,
exceeding the aforesaid costs.
Various interventions aimed at preventing phlebitis in the absence of a CVC were
identified in a literature review: reduced amiodarone concentrations, decreased infusion rates and
duration, use of an in-line filter, and implementation of EBP nursing guidelines. Only one EBP
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approach demonstrated a consistent reduction in phlebitis in the absence of a CVC: EBP nursing
guidelines (Oragano et al., February 2019). Therefore, an EBP nursing guideline rather than
individual interventions was posited to effectually reduce phlebitis incidents. Amiodarone
infusion nurse practice guidelines that facilitated early detection and, thus, reduced phlebitis
incidents and/or severity consisted of practices such as regularly assessing PIV catheter sites,
inserting PIVs dedicated only to amiodarone, using in-line filters, and educating patients about
phlebitis signs and symptoms. An APG also encompasses several patient care standards set forth
by the Infusion Therapy Standards of Practice (2016): an established organizational practice
guideline that describes acceptable actions, provides a basis for clinical decisions, affords
collaborative and safe patient care, and ensures the clinician’s ability to maintain patient safety.
Problem Statement
In the absence of an amiodarone infusion nurse practice guideline, cardiac surgery stepdown patients are experiencing a high rate of phlebitis from peripherally infused amiodarone
despite following manufacturer recommendations.
Literature Review and Synthesis
A literature search was conducted to identify evidence-based interventions shown to
reduce the incidence of amiodarone infusion-related phlebitis. The search was guided by the
following population, intervention, comparison, outcome (PICO) question: “In cardiac surgery
step-down patients, does an amiodarone practice guideline reduce the incidence of phlebitis
compared to current amiodarone infusion administration practices?”
Search Strategy
A literature search was conducted in October of 2020. Databases searched via West
Virginia University libraries included Clinical Key, Cochrane, CINAHL, EbscoHost, and
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PubMed. Google Scholar was also used as a search engine. The combination of keywords used
in the search included: “amiodarone,” “intravenous infusion,” “phlebitis,” “guidelines,” and
“best practices.”
The literature search generated a total of 5,848 articles. Limits were then applied to
include full text, peer-reviewed journal articles published between 2010 to 2020 and written in
English, which produced 1,578 articles. Duplicates were excluded and titles were searched for
keywords and relevance to phlebitis prevention strategies, which yielded 37 relevant studies.
Article abstracts were then scanned and selected based on the following inclusion criteria: adults
18 years or older who received a peripheral infusion of amiodarone, nursing practice guideline as
the primary intervention, and phlebitis reduction as the primary or secondary outcome. A total of
four studies were identified as relevant and included in the synthesis of evidence.
Critical Appraisal of Literature
Four articles were critiqued using Scottish Intercollegiate Guidelines Network (SIGN)
or Larrabee appraisal tools to determine similarities, differences, strengths, and weaknesses in
study design, intervention, and results (Scottish Intercollegiate Guidelines Network, 2020;
Larrabee, 2008). The level of evidence for each piece of literature ranged from one to four. The
study designs included one systematic review and three case-control studies. A total of 2,153
participants were included across the four studies. The primary outcome identified was phlebitis
prevention, or reduction.
Literature Review Synthesis
Three prospective case-control studies used similar methods to identify best practices for
amiodarone infusions (Mindo, August 2018; Murphy et al., 2020; Spiering, November/December
2014).
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After discovering phlebitis rates exceeded the Infusion Nurse Society’s (2011) recommended
five percent occurrence, the researchers of each respective study performed a literature search to
identify best practices. The researchers determined that developing or implementing a guideline
based on EBPs was indicated because a current evidence-based amiodarone infusion guideline
did not exist at their respective facilities. A multidisciplinary team composed of charge nurses,
intravenous therapy nurses, pharmacists, anesthesia, and physicians was then formed to develop
or implement an EBP guideline.
Mindo (August 2018), Murphy et al., (2020), and Spiering (November/December 2014)
each aimed their projects at patients receiving a PIV infusion of amiodarone. However, only two
of the prospective case-control studies had similar patient populations and sample sizes (Mindo,
August 2018; Spiering, November/December 2014). Spiering (November/December 2014) and
Mindo (August 2018) addressed the inclusion of both medical and surgical cardiac patients, but
their sample sizes were limited. In Spiering’s (November/December 2014) study, 34 patients
composed both the control and intervention groups, while Mindo (August 2018) had 35 patients
in the control group and four patients in the interventional group. The third prospective casecontrol study did not disclose the sample size or specific patient demographics (Murphy et al.,
2020).
Results from the three prospective case-control trials varied but post-intervention
phlebitis rates were reduced in two of the studies (Spiering, November/December 2014; Murphy
et al., 2020). Murphy et al. (2020) found phlebitis rates improved by 88 percent and sustained a
reduction of at least 30 percent over six months, which resulted in an overall 46 percent
reduction in phlebitis incidents compared to preintervention data. Spiering (November/December
2014) demonstrated a 47 percent reduction after an amiodarone guideline was implemented.
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Murphy et al. (2020) and Spiering (November/December (2014) also reported phlebitis severity
decreased by 11 and 44 percent, respectively. Mindo (August 2018), found phlebitis increased by
three percent after an amiodarone guideline was implemented. However, the size difference
between the control and intervention groups (35 and 4, respectively) should be taken into
consideration when assessing these results. The preintervention data was collected for six months
compared to four weeks following guideline implementation. Furthermore, after corresponding
with Mindo (August 2018) via email, phlebitis rates had since decreased after implementing an
amiodarone infusion guideline (E. Mindo, personal communication, October 11, 2020).
Oragano et al. (February 2019) conducted a systematic review to identify factors
contributing to amiodarone-related phlebitis development and severity. However, changes to
infusion concentration, rate, or duration presented with mixed results. Oragano et al. (February
2019) found phlebitis rates were lower when amiodarone concentrations were lower (for
example 1.2mg/mL in two studies) compared to higher concentrations (for example, 1.8mg/mL
in seven studies) (OR 0.09, 95% CI 0.05-0.18, p<0.001). Opposing results found increased doses
of amiodarone were not associated with increased rates of phlebitis. Oragano et al. (February
2019) also concluded a correlation does not exist between the rate of infusion and the incidence
of phlebitis. One study within the systematic review used an infusion rate of 2 mg per minute and
had less rates of phlebitis than a study using an infusion rate of 0.75 mg per minute. Furthermore,
the duration of the infusion did not demonstrate a consistent relationship with phlebitis
development, either. Oragano et al. (February 2019) found studies infusing amiodarone for 24
hours had greater phlebitis rates compared to studies using 48-hour infusions; however, one
study resulted in significantly higher rates of phlebitis as the infusion duration increased
(p=0.03). Oragano et al. (February 2019) also determined phlebitis rates may be lower when
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amiodarone is infused as a bolus compared to a continuous infusion (OR 0.05, 95%CI 0.01-0.33;
p=0.002).
Despite mixed results on interventions such as infusion concentration, rate, and duration,
Oragano et al. (February 2019) were able to correlate an increased rate of phlebitis to the absence
of nursing practice guidelines and the use of an in-line filter. Patients developed phlebitis at a 5.8
to 38 percent incidence rate versus a 40 to 85 percent incidence rate in studies where a guideline
was present or absent, respectively (OR 0.13, 95% CI 0.09-0.2, p <0.001). Additionally, rates of
phlebitis ranged from 13.9 to 85 percent when an in-line filter was not used but were only 5.6 to
67% when an in-line filter was used for amiodarone infusions (OR 0.23, 95% CI 0.15-0.34,
p<0.001).
Purpose Statement
The purpose of the project was to implement an amiodarone infusion nurse practice
guideline to reduce the development and severity of phlebitis in cardiac surgery step-down
patients who received a peripheral intravenous infusion of amiodarone.
Quality Caring Model
Joanne Duffy’s Quality Care Model guides evidence-based nursing practice within the
project site’s organization. The Quality Care Model focuses on the structure, processes, and
outcomes of interventions performed during nurse-patient interactions that make the patient feel
“cared for” (Duffy & Hoskins, 2003; Korniewicz & Duffy, n.d). The project goal was to reduce
phlebitis rates and severity by implementing an evidence-based guideline that incorporates
patient-centered care and leads to improved patient care outcomes. The project incorporated the
Quality Care Model because educating patients on phlebitis and including them in surveillance
for amiodarone-related phlebitis ensures signs and symptoms are identified early and appropriate
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interventions are not delayed. Implementing an APG offered standardized PIV amiodarone
infusion practices and the potential to enhance patient care and safety.
Knowledge-to-Action
The Knowledge-to-Action (KTA) framework was used to guide the DNP quality
improvement project aimed at reducing phlebitis rates and severity by implementing synthesized
knowledge into practice through a series of steps. The KTA framework consists of two
components that were applied to the project: knowledge creation and action cycle (Crockett,
2017). Phases initially conducted in the framework included problem identification, knowledge
inquiry, knowledge synthesis, a literature search, and selection of an intervention.
The problem: high rate of phlebitis despite following manufacturer guidelines. The
literature search and knowledge inquiry: the absence of an amiodarone infusion practice
guideline is directly correlated to increased rates of phlebitis, and the project implementation site
did not have an amiodarone guideline. Intervention selection, tailoring, and knowledge synthesis:
an APG was identified and updated (with permission from the author) based on up-to-date
information found throughout the literature.
Phases of the KTA framework that facilitated intervention implementation in various
settings included the adaptation of knowledge into a local context and assessment of barriers and
facilitators to knowledge use (Crockett, 2017). Adaptation of knowledge into a local context: the
project intervention, or APG, targeted CSD patients without a CVC because they are at an
increased risk for developing postoperative AFib that requires a PIV amiodarone infusion, thus
increasing their risk for phlebitis (Slim et. al., December 2007). Assessment of barriers and
facilitators to knowledge use: barriers to implementation included nurse adherence to the APG
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and poor survey participation; however, nurses received education over a one-month period and
questions and barriers were addressed prior to the implementation period.
The next phase of the KTA framework is intervention implementation (Crockett, 2017).
The project’s implementation occurred in four phases. In phase one, following education on
expected documentation, pre-intervention data was collected concerning phlebitis rates and
severity over a five-month period. The second phase included a one-month educational period
about the APG and expected documentation. The third phase consisted of APG implementation
over a second five-month period. During the fourth phase, a survey was sent to nurses to
complete over a one-month period.
The remaining phases of the KTA framework involve implementation and outcome
analysis: monitoring knowledge use, evaluating outcomes, and sustaining knowledge (Crockett,
2017). Following APG implementation, phlebitis rates and severity were compared to preintervention data to determine if the intervention resulted in a statistically significant reduction.
Survey results were used to determine a change in nurses’ perceptions related to phlebitis
incident reporting and the rate of APG implementation.
Specific Aims
Specific aims for the project were:
1. Evaluate the effectiveness of an APG on reducing phlebitis development and/or
severity in CSD patients receiving a PIV infusion of amiodarone
2. Evaluate nurses’ perception regarding the implementation of an APG by surveying
staff who had experience using the guideline.
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Methods
Context
The project was implemented in a 32-bed adult cardiac step-down unit and a 28-bed
CVICU (where CSD patients may remain for an extended period while waiting to be transferred
to a lower acuity floor) located in a large academic hospital. Both units provide treatment for
patients undergoing a variety of cardiac surgeries: coronary artery bypass grafts (CABG), valve
replacements, aneurysm repairs, left ventricular assistive device insertions, and heart transplants.
Patients with a history of cardiac abnormalities and those undergoing cardiac surgery may be
predisposed to developing AFib in the postoperative period, and amiodarone is the medication of
choice for treating arrhythmias at the project site. Thus, the retrospective cohort of interest for
the project was adult CSD patients who received a PIV infusion of amiodarone in the absence of
a CVC.
The risk for developing phlebitis is not as great in intensive care patients because a CVC
is typically available until a patient is transferred to a lower acuity status of care. Hence,
preventing phlebitis in step-down patients can be challenging because CVCs are often not readily
available. Physicians may also be reluctant to insert one solely for an amiodarone infusion due to
the relative risks associated with CVCs, such as infection, pneumothorax, hematoma, and
arrhythmias (Oragano et al., February 2019). Further, nurses lack guidance regarding the
identification of early signs and symptoms of phlebitis due to the absence of an APG, and
manufacturer recommendations have not sufficiently attenuated the risks associated with
amiodarone infusions through PIV sites.
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Intervention
The project design was a retrospective cohort chart review that included CSD patients in
a CSD unit and CVICU. The project consisted of four phases completed over twelve months.
During the first phase, preintervention data on phlebitis rates and severity were collected over a
five-month period following brief education on expected documentation. The data was used to
gain an understanding of true phlebitis occurrence in the project population and to determine if
APG implementation resulted in decreased phlebitis incidents and severity.
During the second phase, nurses were educated on APG utilization over a one-month
period. The guideline targeted CSD patients (without a CVC) who received peripherally infused
amiodarone. An informational posterboard about the APG and expected documentation was
created by the project investigator and placed in employee breakrooms. The project investigator
also created a reference binder (containing the same information as the posterboard) that was
used to provide weekly informal education during nurses’ scheduled shifts. A copy of the
reference binder was placed in each medication room for the duration of APG implementation.
The informal, weekly education was provided in small groups or through individual interactions
in which the project investigator conversed about the project and answered questions. The nurse
manager, supervisors, and clinical preceptors were recruited to provide education or answer
questions in the absence of the project investigator. The APG, posterboard, and reference binder
are presented in Appendix A, Appendix C, and Appendix D, respectively.
After completing the education phase, the APG was implemented for five-months to
reflect the preintervention data collection period. An anonymous postintervention survey
(completion time of 3 minutes) was then sent to nurses by project site leadership via email and
remained open for one month to ensure adequate time for completion. Two follow-up email
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reminders were sent to project site leadership over the one-month period to remind nurses to
complete the survey. Survey results were used to assess nurses’ perceptions on the APG. The
survey can be found in Appendix E.
Plan to Address Gaps in Evidence
Two gaps in evidence existed for the project: standardized survey questions and a
universal EBP APG. A standardized survey to gauge nurse perception on usefulness of an APG
was not identified in the literature. Consequently, a survey was created to assess nurse perception
on using the guideline and vetted for content validity by content experts for the project. The
survey also included a comment section so nurses could identify what works or does not work
because their feedback could be used to enhance the guideline for future use. Similarly, a
universal EBP APG had not been developed, but a similar guideline was used and adapted
between two studies (Spiering, November/December 2014; Mindo, August 2018). For the
project, the same guideline was reorganized and further adapted (with permission from Mindo,
August 2018) to reflect practice capabilities specific to the implementation site (i.e. ultrasoundguided PIV catheters). Hourly PIV site assessments, exclusion of blood draws from the
amiodarone-only PIV catheter, and reference to Lippincott heat/cold procedure were also
incorporated into the guideline as requested by the CSD unit manager. Additionally, a specific
assessment frequency, documentation, and education component was added to assist nurses with
guideline adherence.
Benchmarks
A national benchmark to compare phlebitis rates was not identified, but Infusion Nurse
Society (2011) stated that in any given population of patients receiving a peripheral infusion, the
rate of phlebitis should not exceed five percent. The site for implementation had a reported 20
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percent incidence rate of phlebitis in the project population -with a likely higher incidence
because of underreporting (A. Litwinovich, personal communication, October 7, 2020; L. Pride,
personal communication, November 12, 2020). Results were analyzed to determine if APG
implementation resulted in a clinically and/or statistically significant reduction in phlebitis
incidents. Outcomes were then contrasted to the Infusion Nurse Society’s recommended five
percent maximum phlebitis incidence rate.
Congruence with the Organization’s Strategic Plan.
An evidence based APG supports the university affiliated healthcare organization’s
mission and vision. The mission statement is “to improve the health of West Virginians and all
we serve through excellence in patient care, research, and education” (Mission and Vision, n.d.).
Implementing an evidence-based intervention that addresses phlebitis rates and severity to
enhance patient care supports integration of research into practice. The organization’s vision
includes developing new approaches to improve healthcare through “clinical and translational
research,” and providing patient care that is consistent and integrated for purposes of “delivering
the right care in the right place at the right time” (Mission and Vision, n.d.). Research and
corresponding literature have demonstrated reduced phlebitis rates and severity when a nursing
practice guideline is implemented for patients receiving a PIV infusion of amiodarone in the
absence of a CVC. However, the healthcare organization currently does not have an amiodarone
infusion practice guideline. Therefore, implementing an APG translates current research into
practice and may lead to an organizational change that standardizes amiodarone infusion nursing
practice. Implementing an APG to reduce phlebitis rates and severity for the purpose of
enhancing patient care and outcomes supports the organization’s mission and vision.
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Needs Assessment
Amiodarone’s low pH, high osmolality, and formation of needle-shaped crystals during
infusion increase patients’ susceptibility to developing phlebitis. At the project site, the incidence
of phlebitis continued to exceed Infusion Nurse Society’s (Infusion Nurse Society, 2011)
acceptable 5 percent incidence rate despite following manufacturer recommendations (use of an
in-line filter, infusion through a CVC when possible, and an IV dedicated only to amiodarone).
Incident reports from the project’s host site revealed 20 percent of patients developed phlebitis
from PIV amiodarone infusions. However, this percentage did not reflect the true incidence of
amiodarone-related phlebitis because incident reports were often not submitted (A. Litwinovich,
personal communication, October 7, 2020; L. Pride, personal communication, November 12,
2020). Implementation of an APG was indicated for the project site because a guideline did not
exist.
Strengths, Weaknesses, Opportunities, Threats (SWOT) Analysis
Strengths of the project included implementation of an intervention based on evidence,
decreased iatrogenic harm to patients, and organizational support for quality improvement,
evidence-based projects. The organization has a strong foundation in EBP and was willing to
support different strategies to reduce phlebitis in patients receiving a peripheral amiodarone
infusion.
Weaknesses of the proposed intervention include a small sample size, lack of
generalizability, poor documentation by nurses, and lack of survey participation. The
retrospective cohort included a subset of cardiac patients who received a PIV amiodarone
infusion: CSD patients. The sample size excludes CVICU and step-down patients hospitalized
for cardiac conditions not requiring surgical intervention. The impacts of COVID-19 further
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limited the sample size because surgeries were reduced to open hospital beds for patients
infected with the virus. Furthermore, results may not be generalizable to other patient
populations excluded from the project. Nurses did not document a phlebitis and pain assessment
regularly, making it difficult to analyze if the APG resulted in a statistically significant reduction
in phlebitis. After the implementation period concluded, nurses were asked to participate in a
post-intervention survey that took approximately three minutes to complete. Survey results were
intended to assess the feasibility of implementing an APG into clinical practice; however, limited
staff participated in the survey so feasibility into practice could not be properly assessed.
Opportunities included a broader organizational change following a clinically significant
reduction in phlebitis rate and severity in CSD patients. Additionally, as nurses became
familiarized with the APG there was opportunity to incorporate the guideline into care for other
patients outside of the retrospective cohort who may have received PIV amiodarone infusions.
Threats to the project included poor nurse adherence to the APG, scarcity of
appropriately sized PIV catheters (22-gauge, 1-inch are preferred) and in-line filters (Spiering,
November/December 2014). Nurses who did not recognize amiodarone-infusion related phlebitis
as a problem may have been less willing to follow the APG due increased assessment
frequencies, documentation, and the nature of a practice change. Lack of adequate supplies and
electronic medical record downtime could have hindered nurses’ adherence to the guideline, as
well. Support from the project team and staff education about the incidence and importance of
reducing amiodarone-related phlebitis was provided to dissuade potential indifference to learning
about the new APG and garner support.
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Budget Plan
Budgeting for the project consisted of administrative costs and project supplies required
for educational and reference materials, guideline, and patient education materials.
Administrative costs were minimal because the guideline was incorporated into daily patient care
and used by nurses during scheduled shifts, therefore nurse compensation exceeding the cost of
hourly wages did not occur. Project supplies included paper, ink, printer use, binders, poster
materials, and laminating materials. A phlebitis reference document and copy of the guideline
was placed in each patient room to assist with education, enhance patient-centered care, and
encourage guideline adherence (see Appendix A for APG guideline and Appendix B for phlebitis
reference document). Surveys were sent to employees via email, so no additional costs accrued
(see Appendix E for survey).
Various methods were used to educate nurses on the APG. A poster with information
about the guideline was placed in employee breakrooms so nurses were able to view the
guideline at their leisure. A reference binder with the same information as the poster was also
placed in each medication room for easy access to the educational material. Additionally, clinical
preceptors, supervisors, and nurse managers were recruited to support education and answer
questions in the absence of the project investigator. The project investigator provided weekly
informal education on the APG over a one-month period. Therefore, educational costs did not
exceed the cost for project materials. Table 1 provides a detailed overview of the project budget.
Table 1
Budget Plan
Budget Categories
Administrative Costs
Marketing
Incentives

Personal Funds
$0
$0
$0

Organizational Contributions
RN hourly rate for shift
$0
$0
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Budget Categories
Project Supplies
Totals

Personal Funds
$75
$75

Organizational Contributions
$100
$100

Personnel and Technology
Success of the project was dependent on stakeholder involvement. Nurses in the CSD
unit and CVICU held key roles because they were responsible for implementing the APG.
Advanced nurse practitioners and physician staff were also important stakeholders because they
ordered amiodarone infusions and placed central lines. The nursing director, nurse manager,
supervisors, and clinical preceptors assisted with education and project adherence. Patients and
families receiving medical treatment in the CSD unit and CIVCU were arguably the most
important stakeholders because the APG was intended to enhance patient involvement, care, and
improve outcomes.
The information technology department assisted with accessing patient charts. Access to
the electronic medical record (EMR), medication administration record (MAR) and internet were
required for the project. The EMR and MAR were accessed for data on patient demographics and
information on PIV catheter sites and sizes and amiodarone infusions. The specific data that was
collected can be found in Table 3. Post-intervention surveys were distributed through work
emails.
Sustainability of the Proposed Project
There was no foreseeable negative impact of implementing an APG because there was
not an amiodarone infusion guideline in place at the project site. The goal of the project was to
improve patient outcomes by reducing the occurrence and severity of phlebitis through
implementation of an APG. Additional staff input and satisfaction combined with a perceived
improvement in patient care would support sustainability. Furthermore, continued, and
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broadened use of the APG may lead to future project designs aimed at identifying and measuring
specific variables that could impact the development of phlebitis. Aspects of the APG potentially
burdensome for nurses included the required hourly documentation and potential limited
supplies. Increased documentation requirements and inability to obtain the supplies
recommended by the APG could have impacted sustainability.
Evidence of Key Site Support
The managers, supervisors, and clinical preceptors at the project implementation site
expressed support for the project and dispersed information about the practice change to staff on
the unit. Staff who received information about the practice change expressed excitement and
willingness to participate in the project. See Appendix F for evidence of written support.
Project Timeline
The project was implemented over a twelve-month period following institutional review
board approval. Upon conclusion of the intervention, data was analyzed over a three-month
period. Table 2 provides a detailed outline of the project time periods for each phase of
implementation.
Table 2
Project Timeline
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Study of the Intervention
Nurse adherence to the APG influenced project outcomes. Nurse managers, supervisors,
and clinical preceptors of the CVICU and CSD units were asked to assist with education on the
new guideline and to ensure the APG was being utilized during the implementation period. The
project investigator communicated with the same individuals via weekly emails to provide
updates and to address any issues with data collection that had been encountered. Once the
implementation period concluded, a statistician was consulted to assist with analyzing phlebitis
outcomes and possible variables contributing to phlebitis development. The efficacy of the APG
relative to reduced phlebitis was analyzed by comparing pre- and post-intervention phlebitis
occurrences.
To evaluate perceptions on APG feasibility and its impact on phlebitis reduction, nurses
were sent an anonymous post-intervention survey via work emails. Nurses who participated in
the project were asked to complete the postintervention survey. Four of at least 100 potential
nurses responded. Each submitted survey was assessed for completeness and the results were
taken into consideration when evaluating APG efficacy.
Evaluation Plan
Pertinent information related to phlebitis incidence and severity was collected from
specific sections of the EMR: lines, drains, airway, and wounds (LDAW), MAR, and
demographic tab. The unit managers and clinical preceptors were encouraged to address data
documentation and completion by bedside nurses during unit rounds.
The retrospective cohort of patients was identified via an EMR report consisting of
pharmacy orders created for amiodarone. Those patients listed as step-down under the cardiac
surgery service were then identified. The report was run daily to ensure patients were not missed
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during medicine service transfer or a change in status from floor or intensive care to step-down,
and vice versa.
Once CSD patients were identified, the project investigator recorded and stored data
from the respective EMRs on a password-protected, encrypted device. The medical record
number was recorded during the data collection period to identify corresponding data from a
single EMR during hospitalization but has since been de-identified.
Data from the EMR and the corresponding location where the data was collected from is
presented in Table 3. The preintervention and postintervention data were compared to determine
if the APG produced a statistically or clinically significant reduction in phlebitis incidents and
severity. Demographic data was used to determine if a correlation existed between medical
history or surgery type and phlebitis development.
Table 3
Data Collection for Intervention Outcome Analysis
Patient demographics
• Age
• Gender
• BMI
• Primary
diagnosis or
surgical
procedure
• Vascular
comorbidities
• History of IV
drug use

•
•
•
•
•
•
•
•
•

LDAW flowsheet
PIV catheter site
Insertion date
Removal date
Catheter gauge & length
PIV catheter location
Use of an ultrasound for
placement
Length of time PIV present
Date and time of PIV site
assessment
Site assessment/Phlebitis grade

•
•
•
•

MAR
Date and time amiodarone
infusion started & stopped
If amiodarone infusion was a
bolus or continuous infusion
Date and time the continuous
infusion is halved
If amiodarone infusion is
linked to the PIV catheter
infusion site

An anonymous post-intervention survey (composed of five Likert scale questions and one
open-ended question designed to allow comments) was emailed to nurses following completion
of project implementation (see Appendix E). The survey was intended to assess change in nurse
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perception on using an APG for enhanced patient outcomes. A validated survey was not
identified in the literature. Survey questions were developed using Qualtrics and vetted for
content validity using feedback from content experts at the site of implementation (Qualtrics,
2020). Nurse perceptions about implementing an APG would have been considered positive if
most nurses surveyed reported the guideline reduced the incidence of phlebitis for patients and
was feasible for practice.
Measures
The project had two aims:
1. Evaluate the effectiveness of an APG on reducing phlebitis development and/or severity in
CSD patients receiving a PIV infusion of amiodarone.
Four objectives were established to meet Aim 1 outcomes:
a. Identify the preintervention incidence rate of phlebitis in CSD patients receiving a
PIV amiodarone infusion
b. Educate nursing staff on the APG prior to implementation
c. Implement the APG
d. Compare pre- and post-intervention APG data
Outcomes to evaluate Aim 1 included a reduced incidence of phlebitis and reduced phlebitis
severity when it occurs in patients receiving a PIV amiodarone infusion.
2. Evaluate nurses’ perceptions regarding the implementation of an APG by surveying staff
who had experience using the guideline.
Three objectives were established to meet Aim 2 outcomes:
a. Improve nurse perception of reporting phlebitis incidents
b. Improve reporting of phlebitis
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c. Establish rate of implementation of the APG
Outcomes to evaluate Aim 2 included educating nurses on the APG and completed surveys by
nurses who used the APG.
Analysis
The COVID-19 pandemic and facility-driven changes may have contributed to variation
within the collected data. Two strains of COVID-19 had surged during the post-intervention
period while a surge did not occur during the pre-intervention phase. As a result, CSD patients in
the post-intervention phase were limited. Several facility-driven changes had also occurred
within the implementation period, further impacting data variation. These changes included
amiodarone filters, allotted beds for step-down patients, and documentation requirements. The
amiodarone filter was changed from a Supor 0.2-micron disc filter to a filtered extension set and
the number of step-down beds available decreased from 31 to 19. Initially, a full patient
assessment had to be completed and documented every four hours. However, after modifications
were made to required documentation, only one full patient assessment had to be charted at the
beginning of each shift, followed only by changes from the initial assessment every four hours.
Regardless, an abundance of data was collected for each CSD patient receiving a peripheral
infusion of amiodarone.
Statistical Package for the Social Sciences software was used, and a statistics expert was
consulted to ensure appropriate statistical analysis of data was performed (IBM Corp., 2017).
Chi-square analysis was used to determine if a correlation existed between specific patient or
PIV characteristics and phlebitis development and if there was a statistically or clinically
significant decrease in phlebitis between pre- and post-intervention data. The frequency of
phlebitis development and specific patient and PIV characteristics were also assessed between

24
the two groups. Survey responses were qualitatively assessed for completeness. However, due to
limited survey participation, Likert scaled questions were not analyzed outside of determining
the percentage for each response.
Ethical Considerations
The organization’s ethical standards were upheld throughout all stages of the project to
protect patient rights and safety. Approval from the IRB was sought and obtained prior to project
implementation. To protect patient autonomy and uphold veracity, patients and/or their medical
power of attorney were to be educated on the practice change and were given the ability to
voluntarily participate in phlebitis surveillance. Justice implies fair distribution of care for all.
Implementing an APG that standardizes nursing practice provided all patients with the
opportunity to receive the same high-quality care. No adverse effects have been documented in
the literature; therefore, benefits of the intervention outweigh the risks.
Results
Intervention Steps and Evolution Over Time
The project included four phases completed over the duration of one year. The initial
preintervention phase took place over five months. During that time, data was collected on
current phlebitis rates and severity. Following the initial phase, education was provided on APG
use for one month. Materials used for education included poster boards, a reference binder, and
weekly in-person instruction provided by the project investigator. A copy of the poster board and
reference binder are in Appendix C and Appendix D, respectively. Following education, the
guideline was implemented and data on patient demographics, PIV characteristics, medication
information, and phlebitis occurrence and severity were collected over a second five-month
period. At the end of this phase, an anonymous post-intervention survey was emailed to nursing
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staff at the project site. After project implementation concluded, data was analyzed over a threemonth period. No major modifications were required throughout the project duration. However,
proposed project dates were altered by approximately one month due to re-education required by
the project site’s management. Table 2 provides a detailed outline of the project timeline.
Measures and Outcomes
A total of 104 CSD patients who received a peripheral infusion of amiodarone were
identified throughout the duration of project implementation. Seventy patients were included in
the pre-intervention data collection compared to 34 in the post-intervention data. After guideline
implementation was completed, four out of over 100 nurses responded to the anonymous postintervention survey. Phlebitis was originally estimated to occur at an incidence rate of 20
percent. Pre-intervention data collection yielded 20 incidences of phlebitis among 16 patients for
which IV documentation was complete. This resulted in a higher incidence of phlebitis (28.57%)
than initially estimated (20%). Post guideline data yielded four incidents of phlebitis among four
patients (11.76%) for which IV documentation was complete. Results from Chi-Square analysis
did not produce a statically significant decrease in phlebitis between the two groups (p= 0.178).
However, APG implementation produced a clinically significant reduction in phlebitis incidents
between pre- and post-intervention data. The severity of phlebitis did not differ between the two
groups for PIVs with completed documentation.
Patients who developed phlebitis in the pre-intervention period consisted of ten males and
six females; ages ranged from 61 to 80 years old with a mean of 68.3 years; body mass index
(BMI) ranged from 20.18 to 48.67 with a mean of 31.36. Additionally, two patients had
developed multiple episodes of phlebitis. Two patients were lost due to a transfer from stepdown to intensive care and placement of a CVC. In the post-intervention group, patients who
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developed phlebitis consisted of two males and two females; averaged 71.25 years of age with a
range from 61 to 83; the average BMI was 30.11 and ranged from 27.99 to 35.62. Two subjects
were lost due to transfer from cardiac surgery medicine service and/or change from step-down to
floor or intensive care. Patient medical history varied with hypertension exposed as the most
prevalent among both groups (pre-intervention = 12; post-intervention = 3). Additionally, the
most common procedure among those who developed phlebitis consisted of a CABG or aortic
valve replacement/repair (AVR/r) (pre-intervention: CABG = 5, AVR/r=8; post-intervention:
CABG= 3, AVR/r= 1). The PIV characteristics at sites of phlebitis were predominately 20gauge, 1.88-inch-long PIVs located in the basilic vein for which documentation was completed.
The average time a PIV remained in place for the pre-intervention group was 3,670.8 minutes
(61.2 hours) and ranged from 157 to 7,380 minutes (2.62 to 123 hours). For the post-intervention
group, the average time a PIV remained in placed was 4,293.3 minutes (71.56 hours) and ranged
from 1,410 to 8,931 minutes (23.5 to 148.85 hours). Detailed information on patient
demographics, diagnosis group, and PIV characteristics for those who developed phlebitis is
provided in Table 4.
Table 4
Patient Demographics, Diagnosis Group, and Peripheral Intravenous Catheter Characteristics
of Phlebitis
Total Phlebitis Incidents
Male
Female
Hypertension
Diabetes
Coronary artery disease
Hyperlipidemia
Smoking

Pre-intervention
20
10
6
12
5
6
4
3
Diagnosis Group

Post-Intervention
4
2
2
3
1
2
2
NA
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Pre-intervention
5
8
2

Post-Intervention
3
1

Coronary artery bypass graft/CAD
Aortic Valve Replacement/repair
Mitral Valve Replacement/repair
Aortic aneurysm
Arrhythmia
1
Other
Peripheral Intravenous Catheter Location
Basilic
8
1
Cephalic
4
Antecubital
2
1
Lower/forearm
1
1
Upper arm
2
Wrist/hand
3
1
Peripheral Intravenous Catheter Gauge
22-gauge
1
1
20-gauge
13
3
18-gauge
5
Not available
1
Peripheral Intravenous Catheter Length
1.16 inch
1
1
1.88 inch
6
Not available
13
3
Ultrasound Guided Placement of Peripheral Intravenous Catheter
7
2

To determine if a correlation existed between medical history or surgery type and
phlebitis development, patient demographics, PIV characteristics, and amiodarone infusion data
were collected from both pre- and post-interventional groups’ electronic medical records. ChiSquare analysis was performed to determine if any variable had a statistically significant
correlation to the development of phlebitis or increased severity. When phlebitis development
was identified as the outcome, chi-square analysis yielded no statistical significance among the
following variables: gender, age, body mass index, diagnosis group (CABG/coronary artery
disease, AVR/r, mitral valve replacement/repair, aortic aneurysms, arrhythmia, other), and
history of hypertension, diabetes, coronary artery disease, hyperlipidemia, smoking, use of
ultrasound guided IV, location of PIV, PIV length, number of amiodarone boluses and
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continuous infusions, length of amiodarone exposure, or length of time the PIV catheter
remained in place. Yet, when using phlebitis severity as the outcome, chi-square analysis
indicated the length of time the catheter was in place was statistically significant (p= 0.040).
Complete, detailed information on all patient demographics and diagnosis group and PIV
characteristics are provided in Table 5 and Table 6, respectively.
Table 5
Patient Demographics and Diagnosis Group

Female
Male
Age
BMI
Hypertension
Diabetes
Coronary artery
disease
Hyperlipidemia
Smoking
Coronary artery
bypass graft/CAD
Aortic valve
replacement/repair
Mitral valve
replacement/repair
Aortic aneurysm
Arrhythmia
Other
Total boluses
Total continuous
infusions
Phlebitis
occurrence
Table 6

Pre-intervention patient
Post-Intervention patient
demographics
demographics
Total Percent Average Range Total Percent Average Range
22
31.43
7
20.59
48
68.57
27
79.41
66.8
39-83
65.8
31-83
30.17 16.5630.72
22.2448.67
40.58
48
68.6
28
82.4
35
50
10
29.4
21
30
17
50
18
5
26

25.7
7.1
37.14

15
7
18

44.1
20.6
52.94

21

30

6

17.6

7

10

3
8
5

4.28
11.42
7.14

2

5.88

8

23.53

1.93
1.04
16

28.57

0-7
0-3

1.88
1.06
4

11.8

0-6
0-3
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Peripheral Intravenous Catheter Characteristics
Peripheral intravenous
catheter
Ultrasound guided PIV
Basilic
Cephalic
Upper arm
Lower arm/forearm
Antecubital
Wrist/hand
Other
Not linked
22 g
20
18
4 French
1 inch
1 ¾ inch
1.16 inch
1.75 inch
1.88 inch
Not documented
Less than 4 hours
4 to 8 hours
8 to 12 hours
12 to 24 hours
24 to 36 hours
36 to 48 hours
48 to 60 hours
60 to 72 hours
72 to 84 hours
84 to 96 hours
96 to 120 hours
120 to 144 hours
144 to 168 hours
1 to 2 weeks

Total
184

Percent

77
Peripheral intravenous catheter insertion site
49
39
26
21
21
18
7
3
Peripheral intravenous catheter gauge
13
123
33
5
Peripheral intravenous catheter length
3
2
14
3
56
77
Time catheter remaining in place in hours
2

41.85

2
11
12
15
14
16
14
17
21
11
9
1

1.1
6.0
6.5
8.2
7.6
8.7
7.6
9.2
11.4
6.0
4.9
0.5

26.6
21.2
14.1
11.4
11.4
9.8
3.8
1.5
7.1
66.8
17.9
2.7
1.6
1.1
7.6
1.6
30.4
41.8
1.1
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Four out of over 100 nurses responded to the anonymous post-intervention survey after
guideline implementation concluded. Generally, the nurses agreed that implementing the APG
did not take too much time and enhanced patient care through regularly assessing PIV sites, early
recognition of phlebitis, and reduced phlebitis incidents. One person stated the APG “is helpful.”
Table 7 provides detailed results from the post-intervention survey.
Table 7
Post-intervention Survey Results

The amiodarone infusion
guideline too much time to
implement
Following the amiodarone
infusion guideline assisted me
in identifying signs of
phlebitis earlier than when a
guideline was not in place
My patient’s quality of care is
enhanced when the
amiodarone infusion
guideline is used
The amiodarone infusion
guideline reduced the
incidence of phlebitis in my
patients
Regularly documenting a
phlebitis assessment enhances
patient care
Comment

Strongly
Disagree

Somewhat
Disagree

50%

25%

Neither
Agree nor
Disagree
25%

Somewhat
Agree

Strongly
Agree

75%

25%

25%

50%

25%

50%

25%

25%

25%

25%

50%

One person stated the APG “is helpful”

Unintended Consequences and Missing Data
A few unanticipated matters were encountered throughout the entirety of project
implementation. Two strains of the COVID-19 (Delta and Omicron) surged during the postintervention phase, thus limiting cardiac surgery patients and data. As previously mentioned, the
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number of available step-down beds also decreased which further limited the sample size. Some
patients were also transferred between intensive care, floor, and step-down status or from the
cardiac surgery medicine service. Incomplete documentation and/or inconsistent documentation
among nursing staff and EMR flowsheets also attributed to missing data. For example, the EMR
was sometimes linked to one PIV, but the LDAW had a different PIV documented as infusing
amiodarone. The facility’s change in required assessment documentation frequency occurred
during the post-intervention period, further contributing to missing data because few nurses
charted additional PIV site assessments after an initial assessment was completed. Poor survey
participation also resulted in missing data. Finally, the project site’s pharmacy implemented a
change to amiodarone filters during the education period, which could have impacted phlebitis
development during the post-intervention phase. No unexpected costs were accrued during
project implementation.
Discussion
Summary
Project site investigations revealed a correlation between phlebitis development and
patients receiving a peripheral infusion of amiodarone despite following manufacturer
recommendations. The implementation site also lacked an established APG in place. As a result,
nursing practice among providers could have varied regarding phlebitis surveillance, prevention,
and treatment. Therefore, problem statement factors and specific aims addressed included
standardizing nursing practice and reducing the rate of phlebitis development. A secondary aim
included evaluation of nurses’ perceptions on implementing an APG. Despite low survey
participation, those who responded expressed a positive perception about APG practicality.
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Strengths of the project included an increased awareness of amiodarone-induced
phlebitis, a standardized approach to managing peripherally infused amiodarone, incorporation
of patient-centered care, and a clinically significant decrease in phlebitis incidents despite
statistical insignificance. Additionally, the APG incorporated elements of existing PIV policies
already in place at the institution, such as extracting as much medication as possible from the
PIV site if phlebitis or infiltration occurs, regularly documenting a site assessment, and verifying
infusions with two nurses, particularly during shift change or new infusion orders. The project
itself contributed to increased awareness of amiodarone-induced phlebitis, and the physiology of
phlebitis development was incorporated into educational materials. Provision of a patient
educational component into the APG contributed to patient-centered care because education on
phlebitis signs and symptoms encouraged patients to actively participate in the maintenance of
their own care. Finally, project results demonstrated a clinically significant decrease in the
incidence of phlebitis between pre- and post-intervention data (16.1% reduction).
Interpretation
A positive correlation between the intervention and outcomes may be inferred after
analysis of the results. Because rates of phlebitis decreased, it is likely the APG improved
observation and management of patients receiving a peripheral infusion of amiodarone. More
specific findings related to phlebitis development included patients who predominately
underwent CABG and AVR/r procedures and had a 20-gauge, 1.88-inch PIV in the basilic vein.
However, these findings may be correlated with the increased frequency of these procedures and
type of PIV used among both groups. Additionally, the gauge and length of the PIV
predominately used did not follow APG recommendations. The decrease in phlebitis could
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instead be the result of increased awareness and possible monitoring of the PIV sites rather than
use of a specific PIV gauge and length.
Several confounding factors may have played a role in phlebitis reduction, as well. For
example, amiodarone-related phlebitis and extravasation was already a topic of interest among
some healthcare professionals and graduate students at the time the project was being developed.
The filter used for amiodarone infusions was changed prior to APG implementation, which may
have also contributed to decreased phlebitis incidents. Lack of documentation could have falsely
resulted in reduced phlebitis incidents because some PIVs were removed without a documented
reason, and a site assessment was rarely charted in correlation with the PIV removal. Finally,
supplies used by the facility may have changed, such as PIV catheters. If a catheter was easier to
manipulate during insertion, it may have produced less physical damage rendering a vein more
resistant to further damage by amiodarone.
The post-project surveys were limited but those who responded provided a positive
response regarding APG utilization, citing ease of use and enhanced patient care. Poor survey
participation may be contributed to delayed dissemination to nurses, an influx of travel nurses
who were not familiar with the APG project, and the project investigator’s inability to speak with
nurses directly about completing the survey due to obligations beyond the project site.
The project impacted the people and systems involved with managing patients receiving
peripherally infused amiodarone. The people mainly affected by the intervention were the
patients and participating registered nurses who benefited and/or used the APG. The reduction in
phlebitis revealed a mostly positive impact from likely modifications to nursing practice
recommended by the APG. Nonetheless, variance in guideline usage is unable to be determined
due to inconsistent and/or incomplete charting and lack of survey responses. The system
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impacted by the project consisted of the APG. Implementation of the guideline standardized
nursing practice for patients receiving peripherally infused amiodarone by providing a more
patient-centered and formalized structured process.
Differences between observed and anticipated outcomes may be due to several external
and internal factors. External factors, including the aforementioned facility-driven changes
throughout the project implementation period, were combined with internal factors. For example,
the APG required increased documentation of PIV sites, but facility-driven changes to
documentation decreased the frequency of required assessment documentation. Limited nurses’
time may have also contributed to observed differences in anticipated outcomes and the inability
to confer correlations between patient medical histories and phlebitis development. Further,
nurses may have been resistant to implementing the APG because they felt a process change was
not needed and travel nurses may not have been familiar with the project. Lack of appropriate
supplies may have also impacted implementation of the APG, further contributing to a difference
in anticipated outcomes. Overall, a lack of appropriate documentation and survey responses
limited the ability to evaluate the true impact and nurses’ perception on implementing the APG.
Costs accrued throughout the project were limited and predominately in the form of ink
and paper for educational materials. Additionally, all data were collected electronically from the
EMR limiting the necessity for hard copy data collection tools. Disseminating a physical copy of
surveys rather than, or in addition to, emailing surveys may have been a strategic trade-off that
could have increased participation.
Limitations
The study presents several limitations including lack of generalizability and factors
affecting the internal and external validity of results. Despite support for an evidence-based
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intervention from the project’s site, a convenience sample of CSD patients was utilized for the
study. Floor or intensive care patients and other cardiac and medical patient populations who
received a peripheral amiodarone infusion were excluded from the retrospective cohort of
interest. As a result, the generalizability of results encompassing other patient populations is
absent.
Several factors may have limited the study’s internal validity including an inadequate
sample size, data management limitations, and study design. The recommended sample size
consisted of 128 people to improve statistical validity; however, the project was subject to a
restricted timeline inherent to DNP projects which must be completed prior to graduation. As a
result, the appropriate amount of time to collect pre- and post-intervention data to satisfy the
inclusion of 128 patients was limited. To minimize this limitation, the project was extended over
a year with both pre-and post-intervention phases of the project lasting five months each. Threat
of data management limitations are inherent to projects with a single investigator as the risk for
incorrectly entering data is higher than if multiple investigators were assessing data entry. To
counter this potential threat, the project investigator triple-checked each datum point was entered
correctly to ensure mistakes were minimized. Lastly, the retrospective cohort chart review design
impacts internal validity because the analysis of pre-existing data is subject to bias because the
project investigator was not blinded to the relation between APG implementation and phlebitis
development.
External limitations related to the study include lack of adherence to the APG and factors
related to the study design. If nurses did not agree a practice change was indicated, it is likely the
guideline was viewed as unnecessary and participation unwarranted. Confounding factors, such
as lack of appropriate equipment, may have impacted nurses’ ability to adhere to the APG as
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well. Facility-driven changes to required documentation could have further resulted in the
absence of necessary data from the medical record. Finally, nurses’ time constraints within their
clinical day may have contributed to missing or conflicting data within the medical record.
Efforts to minimize or adjust for limitations included educating nurses on the data that
would be collected for the project before implementation. Table 3 was provided to nurses during
staff huddles to give an understanding of what data the project required for successful
completion. Email communication with project site leadership was also utilized to address issues
encountered during data collection periods.
Conclusions
An EBP guideline aimed at decreasing amiodarone-induced phlebitis was identified as an
effective intervention following an extensive literature review. For the project, implementation
of an APG increased awareness of amiodarone-induced phlebitis and set a standardized nursing
practice for peripheral amiodarone infusions. This was evidenced by a 16.1% clinically
significant reduction in phlebitis incidents between pre- and post-intervention data. Additionally,
the four nurses surveyed suggested the APG was useful for enhancing patient care.
The sustainability of the APG at the site of study depends on a few significant factors
including interprofessional collaboration, consistency, and expansion. If nurses, nurse leadership,
physicians, APRNs, and pharmacists collaborated on adjustments and updated the guideline as
needed based on knowledge credited to respective specialties and new EBP recommendations, it
is likely more practitioners will become invested in consistently using the APG. Furthermore, the
project site could require and monitor adherence to the guideline as part of patient safety efforts
given the positive correlation demonstrated between APG usage and reduced rates of phlebitis
development. Expanding guideline usage across all patient populations who receive peripheral
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amiodarone infusions would not only contribute to potential generalizability but also enhance the
quality and consistency of care patients receive throughout the entirety of hospitalization.
Finally, the recommended measures to support APG sustainment align with the organization’s
strategic plan for the provision of excellent patient care through research, education, and the
translation of research into practice.
Identified facilitators and barriers encountered during the project may also impact the
project’s future sustainability. Facilitators included the facility’s recognition of amiodaroneinduced phlebitis as a problem and willingness to participate in an EBP project aspiring to
resolve the issue. Department head support and nurse interest and willingness to learn about the
problem and project also reinforced facilitation. Barriers included a lack of documented
adherence to the APG. However, increasing nurse stakeholder involvement could challenge the
barriers to APG adherence. This is especially true if nurses actively participate within a
collaborative team to enhance the APG. Therefore, future stakeholders could encompass more
nurses, physicians, nurse practitioners, physician staff, and facility leaders and expand to
pharmacists and professional students. Broadening stakeholder involvement may motivate
practitioners to improve upon current PIV and infusion practices and further support APG
sustainability.
Recommendations can be made regarding the potential spread of the project to other
contexts and implications for practice. The study was limited to a subset of the vast cardiac
patient population treated within the large academic medical facility and healthcare system. Use
of the APG could be spread to the remaining cardiac patient population, as well as patients
seeking treatment for other medical conditions. If extended facility- and system-wide, consistent
care for patients receiving peripherally infused amiodarone is likely to occur between transfers to
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other hospital units or medical centers. The APG could also be adjusted to incorporate other
caustic medication infusions in the future as well.
A cost analysis of the APG may prove beneficial to assessing the impact the guideline
has on decreasing healthcare costs and length of stay associated with decreased phlebitis
incidences because these specific costs were not identified during the literature search.
Additional infusion related complications such as infiltration and extravasation were also not
addressed during this project. For these reasons, future studies could expand on the impact the
APG has on preventing infiltration and extravasation, including cost and length of
hospitalization.
The next steps should consist of developing studies capable of broadening the scope of
knowledge on amiodarone-induced phlebitis and to refine the APG. Subsequent studies should
include a broadened patient population and sample size to improve generalizability and the
possible significance the APG has on reducing phlebitis development. Additionally, statistically
significant results from the project suggest that phlebitis severity positively correlates with the
length of time a PIV remains in place. This finding challenges the project facility’s current policy
on the length of time an ultra-sound guided PIV may remain in place. Thus, additional research
into PIV characteristics and the length of time a catheter can safely remain in place for
peripherally infused amiodarone is warranted. Finally, future studies should continue to assess,
refine, update, and expand the APG as new evidence-based practices are established.
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Appendix A
Amiodarone Infusion Nurse Practice Guideline
Practice
1. Use a dedicated line
a. Always have two peripheral IV catheters
i. One for amiodarone ONLY & one for other medications
ii. Avoid collecting blood from the amiodarone ONLY IV*
iii. Label Amiodarone only PIV on catheter dressing*
b. No other medication may be infused or injected with amiodarone
2. IV catheter
a. Use the smallest catheter possible in the largest vein
i. 22g, 1-inch Ultrasound guided IV is preferred if patients meet the following
criteria:
a. Age 60 years old or greater
b. Obesity
c. Veins not visible or palpable
d. Failure after 2 attempts at traditional IV catheter insertion
e. Current or history of IV drug abuse
f. History of chronic conditions:
i. Anemia, diabetes, end-stage renal disease, vascular disease,
chemotherapy, etc.
g. Frequent hospitalizations
ii. In emergent situation, may use whatever catheter is available, but must switch
to appropriate catheter as quickly as possible
b. Do NOT use an area of joint flexion
3. Use separate filters for both amiodarone bolus and continuous infusion
4. Remove the IV at first sign of PAIN, redness, infiltration or phlebitis
(Pain often presents before other signs of phlebitis: i.e. redness)
a. Aspirate as much medication from the catheter as possible prior to removal
i. After removal:
1. Clean area with CHG
2. Apply ice pack (*Refer to Lippincott procedure)
3. Elevate the affected arm
4. Document intervention and phlebitis scale in LDAW
5. Continue assessing & documenting site for 96 hours after catheter removal
ii. If infiltrated, refer to Vascular Access Devices: Phlebitis and Infiltration
policy under WVUH Nursing Policies, Procedures, & Standards of
Professional Practice
5. Continue the infusion through a different IV catheter
6. If infusion ordered longer than 24 hours, collaborate with healthcare team and address
possible PICC or other CVC placement
Assessment

43
1. Assess the IV site prior to infusion
a. Assess for pain or redness, and assure an adequate flush with 10mL of NS
b. If any issues, document on infiltration and phlebitis scale and pain in LDAW
2. Assess the IV site immediately after bolus or continuous infusion is completed
a. Remove IV for any signs of pain and document in LDAW
3. IV site inspection and infusion (bolus or continuous) must be assessed and documented
by two RNs during shift report
4. IV site assessment and documentation must be completed HOURLY* DURING
AMIODARONE INFUSION and continue every 4 hours for 96 hours after infusion
discontinued and/or IV catheter removed.
a. *Between 0000 and 0500, assessment and documentation may occur every four
hours, or whenever the nurse must enter a patient’s room for care
b. Continue to document and assess the IV site every 4 hours after the IV catheter
has been removed
Documentation
1. LDAW
a. In LDAW flowsheet, go to add rows. In group, search the descriptor or the
associated number, as listed below, if the row is not already available.
i. Pain
1. If pain is present, chart “painful” under peripheral IV site
assessment. Use comment box on site assessment to document
pain score (0-10)
ii. Phlebitis/Pain intervention
1. Add row if not yet available on LDAW: Pain intervention (see
note) (7705)
iii. Document use of an in-line filter for amiodarone bolus and/or
continuous infusion
1. Comment (22998) to chart use of in-line filter if not yet
available on LDAW
2. PHLEBITIS SCORE and IV site assessment must be charted HOURLY for each
peripheral IV site in which amiodarone is infusing (See Assessment section for more
detail)
3. Medication
a. Link Amiodarone to infusion site in MAR
b. If infusing other medications through amiodarone IV site is unavoidable, link
medications given through same IV site in MAR
4. Incident report must be filed for any phlebitis score greater than 0
Educate patient on signs of phlebitis
Instruct patient to notify RN immediately at first sign of pain, redness, or other changes around
the IV site
Additional EPIC Education Resources:
• On MAR go to Clinical Pharmacology then Education
• Pick either Medcounseler sheets or Discharge Instructions
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•

“Search by Condition”
o Phlebitis
o Phlebitis, easy-to-red

Note. Guideline adapted with permission from Elaine Mindo (Mindo, August 2018).
* denotes practices incorporated into the guideline at the request of the CSSDU manager.
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Appendix B
Phlebitis Reference Document for Patient Education
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Notify your nurse if you are experiencing
any of the following symptoms at an IV site
Signs and Symptoms
Pain
Tenderness
Burning
Redness
Swelling
Warmth
Induration
Area of skin becomes firm, but not as hard as bone

Purulence
Pus around the IV site

Palpable cord
(Spiering, November/December 2014; Infusion Nurses Society, January/February 2016;
Oragano, Patton, & Moore, February 2019)
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Appendix C
Educational Poster Board
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Appendix D
Educational Reference Binder Material

Amiodarone Infusion Nursing Practice Guideline
Quality Improvement Project

Amiodarone Crystals (Raval, M.K. et al., 2010)

WVU Medicine Policies
Policy XXII.16-A Vascular Access Devices: Peripheral & Midline catheters
Policy XXII.16-C: Vascular Access Devices: Phlebitis & Infiltration
Estimated Preintervention Data:

Total patients meeting inclusion criteria: 70

Total phlebitis occurrence: 20 (28.57%)
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Phlebitis

25 to 85% of patients receiving peripherally infused amiodarone develop phlebitis
•

Phlebitis is defined as inflammation of the vein wall caused by chemical, physical, or
infective mechanisms. Signs and symptoms include pain, tenderness, burning, redness,
swelling, warmth, induration, purulence, and/or a palpable cord.

•

Phlebitis related complications a patient may encounter include discomfort, fever, sepsis,
increased length of hospital stay & healthcare costs, and sometimes plastic surgery to repair
damaged tissue.

•

Chemical properties of amiodarone lend to the development of phlebitis: concentration,
solution dilution, speed of administration, & precipitate formation, osmolarity [255-345
mOsm/L] & pH [3.46-4.35].

•

Physical causes of phlebitis include catheter material, length, & lumen size, and poor
insertion technique and/or maintenance.

•

During amiodarone infusion, needle-shaped crystals can form and damage local tissue This
crystallization may occur at any time during administration. During storage, amiodarone may
breakdown into particles due to the drug’s instability, poor quality control, or poor
compounding processes. Further, amiodarone can leach out plasticizers from polyvinyl
chloride that also irritate the vessel wall. This leaching increases at higher amiodarone
concentrations and lower flow rates.

•

Precipitation may be directly correlated with phlebitis making rapid dilution of the
medication an important variable in phlebitis development. Slow injection into a constant
flowing blood stream or into a large volume produces rapid dilution. A very slow injection,
especially if into a large vessel, will eliminate precipitation because the drug becomes more
quickly soluble. Further, injection into small veins or those with a low flow rate results in an
increased local venous concentration of drug and an increased likelihood of precipitation and
purulence.

•

Amiodarone-related phlebitis can occur up to 96 hours after catheter removal.

•

Risk factors for phlebitis include:
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o
o
o
o
o
o
o
o
o
o

Multiple manipulations of infusion delivery system
Large gauge and length of catheter
Catheter material and configuration
Failure to stabilize VAD adequately
Patient age, condition, acuity
Administration of irritating infusates (acid/alkaline pH & high osmolarity)
Inadequate VAD insertion technique
Inadequate skin antisepsis
Inadequate care and maintenance practices
Extended dwell time
Osmolarity is the number of particles of solute per liter
of solution.
Osmolality is the number of particles of solute per
kilogram of solvent, or the measure of how much one
substance has dissolved into another substance
• The greater the concentration of the substance
dissolved, the higher the osmolality
• Amiodarone’s solution osmolarity and pH
increases the risk of damaging vein intima
and may result in phlebitis when
administered intravenously

Literature Review
Healthcare organizations in which an amiodarone infusion guideline was not in place
were experiencing phlebitis rates greater than the Infusion Nurses Society recommended 5%.
Once a guideline was instituted, phlebitis rates were reduced by up to 47% and severity was
reduced by up to 44%.
Researchers of a systematic review assessed several variables contributing to
amiodarone-related phlebitis and severity: infusion concentration, rate, and duration. These
variables produced conflicting results and the authors of the systematic review were unable to
conclude any existing correlations. However, the researchers identified a positive correlation
between increased rates of phlebitis and the absence of a nursing practice guideline and use of inline filters. When an in-line filter was not used for amiodarone infusions, rates of phlebitis
ranged from 13.9 to 85 percent compared to rates of 5.6 to 67% with an in-line filter. Studies
within the systematic review that did not have a guideline experienced phlebitis rates of 40 to
85% whereas studies with a guideline in place experienced phlebitis rates of 5.8 to 38%.
Therefore, the systematic review concluded amiodarone infusion nursing practice guidelines and
use of in-line filters is indicated to reduce phlebitis rates.
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*Highlighted information represents changes from current practice
Amiodarone Infusion Nurse Practice Guideline
Practice
7. Use a dedicated line
a. Always have two peripheral IV catheters
iv. One for amiodarone ONLY & one for other medications
v. Avoid collecting blood from the amiodarone ONLY IV*
vi. Label Amiodarone only PIV on catheter dressing*
b. No other medication may be infused or injected with amiodarone
8. IV catheter
a. Use the smallest catheter possible in the largest vein
i. 22g, 1-inch Ultrasound guided IV is preferred if patients meet the
following criteria:
a. Age 60 years old or greater
b. Obesity
c. Veins not visible or palpable
d. Failure after 2 attempts at traditional IV catheter
insertion
e. Current or history of IV drug abuse
f. History of chronic conditions:
i. Anemia, diabetes, end-stage renal disease,
vascular disease, chemotherapy, etc.
g. Frequent hospitalizations
2. In emergent situation, may use whatever catheter is available,
but must switch to appropriate catheter as quickly as possible
b. Do NOT use an area of joint flexion
9. Use separate filters for both amiodarone bolus and continuous infusion
10. Remove the IV at first sign of PAIN, redness, infiltration or phlebitis
(Pain often presents before other signs of phlebitis: i.e. redness)
a. Aspirate as much medication from the catheter as possible prior to
removal
i. After removal:
1. Clean area with CHG
2. Apply ice pack (*Refer to Lippincott procedure)
3. Elevate the affected arm
4. Document intervention and phlebitis scale in LDAW
5. Continue assessing & documenting site for 96 hours after
catheter removal
ii. If infiltrated, refer to Vascular Access Devices: Phlebitis and
Infiltration policy under WVUH Nursing Policies, Procedures, &
Standards of Professional Practice: Policy XXII.16-C
11. Continue the infusion through a different IV catheter
12. If infusion ordered longer than 24 hours, collaborate with healthcare team and address
possible PICC or other CVC placement
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*Please note 22g, 1-inch catheter is preferred but recognized it may not always be readily
available. As such, use the smallest gauge and length catheter available.
Assessment
5. Assess the IV site prior to infusion
a. Assess for pain or redness, and assure an adequate flush with 10mL of NS
b. If any issues, document on infiltration and phlebitis scale and pain in LDAW
6. Assess the IV site immediately after bolus or continuous infusion is completed
a. Remove IV for any signs of pain and document in LDAW
7. IV site inspection and infusion (bolus or continuous) must be assessed and documented
by two RNs during shift report
8. IV site assessment and documentation must be completed HOURLY DURING
AMIODARONE INFUSION and continue every 4 hours for 96 hours after infusion
discontinued and/or IV catheter removed.
a. *Between 0000 and 0500, assessment and documentation may occur every four
hours, or whenever the nurse must enter a patient’s room for care
b. Continue to document and assess the IV site every 4 hours after the IV catheter
has been removed
*With each assessment, there should be corresponding documentation as described in the
following section of the guideline
*After an infusion or IV is discontinued, continue to chart a phlebitis scale, pain assessment, and
any intervention that is performed for 96 hours.

Documentation
5. LDAW
a. Pain
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i. If pain is present, chart “painful” under peripheral IV site
assessment. Use comment box on site assessment to document pain
score (0-10)

a. Phlebitis/Pain
Intervention

b. Phlebitis/Pain Intervention

c. Document use of an in-line filter for amiodarone bolus and/or continuous
infusion

2. PHLEBITIS SCORE and IV site assessment must be charted HOURLY for each
peripheral IV site in which amiodarone is infusing (See Assessment section for more
detail)

3. Medication
a. Link Amiodarone to infusion site in MAR
b. If infusing other medications through amiodarone IV site is unavoidable, link
medications given through same IV site in MAR
4. Incident report must be filed for any phlebitis score greater than 0
*Phlebitis scale and pain score should be documented with each assessment (hourly, at time of
new infusion, after infusion completed)
*Use of an in-line filter should be charted once with each new amiodarone order
*Phlebitis/Pain Intervention should be charted with each intervention
*Information that will be collected from the Kardex, LDAW, and MAR for project
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Patient
LDAW flowsheet
demographics
• Age
• PIV catheter site
• Gender
• Insertion date
• BMI
• Removal date
• Primary
• Catheter gauge & length
diagnosis or
• PIV catheter location
surgical
• Use of an ultrasound for
procedure
placement
• Vascular
• Date and time of PIV site
comorbidities
assessment
• History of IV
• Length of time PIV present
drug use
before amiodarone infusion
started
• Length of time PIV present
before phlebitis occurrence
• Pain score at PIV site
• Phlebitis grade
• If use of an in-line filter is
charted for both bolus and
continuous drip

MAR
•
•
•
•
•
•

Date and time
amiodarone infusion
started & stopped
If amiodarone infusion
was a bolus or
continuous infusion
Date and time the
continuous infusion is
halved
If use of an in-line filter
is charted for both bolus
and continuous infusion
If amiodarone infusion
is linked to the PIV
catheter infusion site
If other medications are
linked or administered
through the same PIV
catheter as amiodarone

Educate patient on signs of phlebitis
Instruct patient to notify RN immediately at first sign of pain, redness, or other changes around
the IV site
Additional EPIC Education Resources:
• On MAR go to Clinical Pharmacology then Education
• Pick either Medcounseler sheets or Discharge Instructions
• “Search by Condition”
o Phlebitis
o Phlebitis, easy-to-read
*The following information will be laminated and placed in each patient room to facilitate
patient education and participation in reporting and monitoring IV sites for signs of phlebitis.
*The EPIC education resources should be given to each patient receiving amiodarone & used to
provide further education.
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Phlebitis Reference Tool for Patient Education

Notify your nurse if you are experiencing any of the following symptoms at an IV
site
Signs and Symptoms
Pain
Tenderness
Burning
Redness
Swelling
Warmth
Induration
Area of skin becomes firm, but not as hard as bone
Purulence
Pus around the IV site
Palpable cord
(Spiering, November/December 2014; Infusion Nurses Society, January/February 2016; Oragano, Patton, & Moore,
February 2019)
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Notify your nurse if you are
experiencing any of the
following symptoms at an IV
site
Signs and Symptoms
Pain
Tenderness
Burning
Redness
Swelling
Warmth
Induration
Area of skin becomes firm, but not as hard as
bone
Purulence
Pus around the IV site
Palpable cord
(Spiering, November/December 2014; Infusion Nurses Society, January/February 2016;
Oragano, Patton, & Moore, February 2019)
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Amiodarone Infusion Nurse Practice Guideline
Practice
13. Use a dedicated line
a. Always have two peripheral IV catheters
i. One for amiodarone ONLY & one for other medications
ii. Avoid collecting blood from the amiodarone ONLY IV*
iii. Label Amiodarone only PIV on catheter dressing*
b. No other medication may be infused or injected with amiodarone
14. IV catheter
a. Use the smallest catheter possible in the largest vein
i. 22g, 1-inch Ultrasound guided IV is preferred if patients meet the
following criteria:
a. Age 60 years old or greater
b. Obesity
c. Veins not visible or palpable
d. Failure after 2 attempts at traditional IV catheter
insertion
e. Current or history of IV drug abuse
f. History of chronic conditions:
i. Anemia, diabetes, end-stage renal disease,
vascular disease, chemotherapy, etc.
g. Frequent hospitalizations
2. In emergent situation, may use whatever catheter is available,
but must switch to appropriate catheter as quickly as possible
b. Do NOT use an area of joint flexion
15. Use separate filters for both amiodarone bolus and continuous infusion
16. Remove the IV at first sign of PAIN, redness, infiltration or phlebitis
(Pain often presents before other signs of phlebitis: i.e. redness)
a. Aspirate as much medication from the catheter as possible prior to
removal
i. After removal:
1. Clean area with CHG
2. Apply ice pack (*Refer to Lippincott procedure)
3. Elevate the affected arm
4. Document intervention and phlebitis scale in LDAW
5. Continue assessing & documenting site for 96 hours after
catheter removal
ii. If infiltrated, refer to Vascular Access Devices: Phlebitis and
Infiltration policy under WVUH Nursing Policies, Procedures, &
Standards of Professional Practice
17. Continue the infusion through a different IV catheter
18. If infusion ordered longer than 24 hours, collaborate with healthcare team and address
possible PICC or other CVC placement
Assessment

60

9. Assess the IV site prior to infusion
a. Assess for pain or redness, and assure an adequate flush with 10mL of NS
b. If any issues, document on infiltration and phlebitis scale and pain in LDAW
10. Assess the IV site immediately after bolus or continuous infusion is completed
a. Remove IV for any signs of pain and document in LDAW
11. IV site inspection and infusion (bolus or continuous) must be assessed and documented
by two RNs during shift report
12. IV site assessment and documentation must be completed HOURLY* DURING
AMIODARONE INFUSION and continue every 4 hours for 96 hours after infusion
discontinued and/or IV catheter removed.
a. *Between 0000 and 0500, assessment and documentation may occur every four
hours, or whenever the nurse must enter a patient’s room for care
b. Continue to document and assess the IV site every 4 hours after the IV catheter
has been removed
Documentation
6. LDAW
a. In LDAW flowsheet, go to add rows. In group, search the descriptor or the
associated number, as listed below, if the row is not already available.
i. Pain
1. If pain is present, chart “painful” under peripheral IV site
assessment. Use comment box on site assessment to document
pain score (0-10)
ii. Phlebitis/Pain intervention
1. Add row if not yet available on LDAW: Pain intervention (see
note) (7705)
iii. Document use of an in-line filter for amiodarone bolus and/or
continuous infusion
1. Comment (22998) to chart use of in-line filter if not yet
available on LDAW
7. PHLEBITIS SCORE and IV site assessment must be charted HOURLY for each
peripheral IV site in which amiodarone is infusing (See Assessment section for more
detail)
8. Medication
a. Link Amiodarone to infusion site in MAR
b. If infusing other medications through amiodarone IV site is unavoidable, link
medications given through same IV site in MAR
9. Incident report must be filed for any phlebitis score greater than 0
Educate patient on signs of phlebitis
Instruct patient to notify RN immediately at first sign of pain, redness, or other changes around
the IV site
Additional EPIC Education Resources:
• On MAR go to Clinical Pharmacology then Education
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•
•

Pick either Medcounseler sheets or Discharge Instructions
“Search by Condition”
o Phlebitis
o Phlebitis, easy-to-red

* denotes practices incorporated into the guideline at the request of the CSSDU manager.

Documentation
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Appendix E
Amiodarone Infusion Nurse Practice Guideline Post-Intervention Survey
Qualtrics Survey Software

11/15/20, 8:38 AM

Amiodarone Infusion Guideline Satisfaction
Q1. If you had experience using the amiodarone infusion guideline
during the study period, please rate how much you personally
agree or disagree with the following statements.
Strongly
disagree

Somewhat
disagree

Neither agree
nor disagree

Somewhat
agree

Strongly
agree

The amiodarone infusion
guideline took too much
time to implement
Following the
amiodarone infusion
guideline assisted me in
identifying signs of
phlebitis earlier than
when a guideline was
not in place
My patient's quality of
care is enhanced when
the amiodarone infusion
guideline is used
The amiodarone infusion
guideline reduced the
incidence of phlebitis in
my patients

https://wvu.ca1.qualtrics.com/Q/EditSection/Blocks/Ajax/GetSurveyP…xtSurveyID=SV_74lfXMuoGUI6xP7&ContextLibraryID=UR_5umxKPzJWIgVXud

Page 1 of 2
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Qualtrics Survey Software

11/15/20, 8:38 AM

Regularly documenting
a phlebitis assessment
enhances patient care

Q2. Provide any comments on your experience using the
amiodarone infusion practice guideline.

Powered by Qualtrics

https://wvu.ca1.qualtrics.com/Q/EditSection/Blocks/Ajax/GetSurveyP…xtSurveyID=SV_74lfXMuoGUI6xP7&ContextLibraryID=UR_5umxKPzJWIgVXud

Page 2 of 2
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Appendix F
Evidence of Support

7KLV GRFXPHQW LV WR YHULI\ WKDW .ULVWHQ &RWWULOO D :HVW 9LUJLQLD 8QLYHUVLW\ 'RFWRU RI 1XUVLQJ
3UDFWLFH VWXGHQW KDV SHUPLVVLRQ WR FRQGXFW WKH SURSRVHG SURMHFW UHJDUGLQJ $PLRGDURQH
LQώOWUDWLRQ LQ WKH &DUGLRYDVFXODU ,QWHQVLYH &DUH 8QLW DW 5XE\ 0HPRULDO 7KLV SURMHFW LV QRW
UHODWHG WR WKH VWXGHQWͭV HPSOR\PHQW DW 5XE\ 0HPRULDO 7KH SURMHFW ZLOO QRW EH LQLWLDWHG SULRU WR
WKH VWXGHQW UHFHLYLQJ DSSURYDO IURP :HVW 9LUJLQLD 8QLYHUVLW\ͭV ,QVWLWXWLRQDO 5HYLHZ %RDUG
,5%  7KH VWXGHQWͭV IDFXOW\ RI UHFRUG 'U 2VWURZVNL '13 $351 &51$ ZLOO DOVR EH
RYHUVHHLQJ WKH SURMHFW , DV WKH PDQDJHU ZLOO HQVXUH LQWH Q W\ RI WKH SURMHFW UHPDLQV LQWDFW DQG



D DUG WR WKH SURMHFW

'DWH 0a
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